SEMINAR | Unlocking new therapeutic targets for pancreatic cancer

Evasion of cell death is a major clinical challenge for malignancies. The seminar will introduce a purpose-built international pancreatic cancer registry, linked to fully annotated patient biospecimens, and an organoid biobank that spans the full spectrum of molecular sub-types. As part of a highly collaborative program we exploited single cell, bulk transcriptomics and proteomics analyses to describe the inter and intra-patient heterogeneity within intrinsic, necroptotic and extrinsic cell death machinery. This study highlights the unexplored potential of targeted therapies that induce necroptosis and provides proof-of-principle evidence for clinical trials specifically augmenting the extrinsic cell death pathway.

is a laboratory head in the Personalised Oncology Division at the Walter and Eliza Hall Institute of Medical Research. She is co-founder and CSO of Nelcanen Therapeutics, the scientific lead of the Hemstritch Centre of Excellence for Pancreatic Cancer Research and holds honorary appointments at the University of Melbourne. Prof Putoczki completed her undergraduate research training at the University of Toronto, Canada, her PhD in Molecular Biology and Biochemistry at the University of Canterbury, New Zealand and her postdoctoral training at the Ludwig Institute for Cancer Research, Australia. Her team have received continuous support from multiple (inter)national funding bodies, which has enabled publications in top tier journals including Cancer Cell, Immunity, Nature and Cell.

This seminar will be held on October 15 in Lecture Theatre B, Level 7 VCCC in-person and via Zoom between 11:30am-12:30pm.

The seminar will be chaired by Professor Fred Hollande and will be followed by light refreshments in the atrium.

Know what’s Happening Next — before everyone else does.

Get App

Host or Publisher University of Melbourne Centre for Cancer Research